Related Experiment Videos
HIV resistance testing: an update
1Department of Laboratory Medicine, University of Connecticut Medical School, Farmington, Connecticut, USA. jaslanz@harthosp.org
Annals of Clinical and Laboratory Science
|December 3, 2002
Summary
HIV resistance testing guides optimal combination therapy by identifying mutations. This allows selection of effective antiviral agents with fewer side effects, improving treatment outcomes for HIV patients.
Area of Science:
- Virology
- Infectious Diseases
- Pharmacology
Background:
- Antiretroviral therapy is crucial for managing HIV infection.
- Emergence of drug resistance necessitates personalized treatment strategies.
- Optimizing combination therapy requires understanding resistance mechanisms.
Purpose of the Study:
- To review current FDA-approved HIV antiviral agents and their mechanisms of action.
- To discuss HIV genetic mutations conferring resistance to antiviral drugs.
- To evaluate genotypic and phenotypic resistance testing methods for HIV treatment.
Main Methods:
- Literature review of current HIV therapeutics and resistance mechanisms.
- Analysis of Food and Drug Administration (FDA) approved antiviral agents.
- Comparative evaluation of genotypic and phenotypic resistance testing.
Main Results:
- Identification of specific resistance mutations aids in selecting effective antiretroviral drugs.
- Genotypic testing provides rapid detection of resistance mutations.
- Phenotypic testing measures drug susceptibility directly but is more complex.
Conclusions:
- Resistance testing is essential for tailoring HIV combination therapy.
- Both genotypic and phenotypic tests offer valuable information with distinct advantages and disadvantages.
- Informed drug selection based on resistance profiles maximizes therapeutic benefit and minimizes toxicity.